¶}µo¨âºØ·sÃĨü®À Eli Lilly¥þ²yµôû8%
¡i©ú³ø±M°T¡j¬ü°ê§¨ÓÃļt(Eli Lilly & Co.)©P¥|»¡¡A¥¦n¦b¥þ²yµô´îû¤u¶¤¥î8%¡A§Y¤j¬ù3,500¤H¡C¹L¥h¤@¦~¸ÓÃļt¶}µo¨âºØ¥i¯àªººZ¾PÃĹJ¨ì®À§é¡A§Æ±æÂǵôû¸`¬Ù¦¨¥»¡C
§¨ÓÃļt±N±q2018¦~¶}©l¡A¥þ²yµôû¬ù3,500¤H¡A¨C¦~¸`¬Ù¬ù5»õ¤¸¡C¸Ó¤½¥qªÑ²¼©P¥|¦¬¥«81.54¤¸¡A¤É1.03¤¸¡A©Î1.28%¡C
¤½¥q¹w´Á¦h¼Æµôû¨Ó¦Û¥¦¦b¬ü°ê´£¨Ñªº¦ÛÄ@´£¦°h¥ðp¹º¡C¥¦¤]±NÃö³¬·R²üµØ¦{ªº¤u¼t¡A¥H¤Î·s¿A¦è¦{»P¤¤°êªº¬ã¨s¤Îµo®i¿ì¤½«Ç¡C
ÃÒ¨é¦æMorningstar¤ÀªRû±d¿Õ¦ò(Damien Conover)ªí¥Ü¡A§¨ÓªºÀç·~§Q¼í²v»¹©ó¹ï¤â¤½¥q¡C±d¿Õ¦ò»¡¡G¡u§¨Óªº¬ãµo¦û¾P°âÃB¤ñ¨Ò¡A¹L©¹¨â¦~µy·L°¾°ª¡C¨ä±¹¬Iªº³¡¤À¥Øªº¡A¬O½T«O³oÓÀç·~§Q¼í²v§ó®²¦X¾ãÓ¶°¹Î¡C¡v
§¨Ó¤µ¦~7¤ë©ÜÅS¡A¥¦¦b¶}µoªºÃþ·Àã©ÊÃö¸`ª¢·sÃÄbaricitinib¡A¥i¯à¦³¼Æ¦~ªº©µ»~¡A¦]¬°¬ü°ê¹ª«¤ÎÃĪ«ºÞ²z§½(U.S. Food and Drug Administration)©Úµ´§åã·sÃÄ¡An¨D¼W¥[¤@¶µÁ{þH¹êÅç¡C
¦¹¥~¡A§¨ÓÃļt¥h¦~11¤ëªº¦Ñ¦~è§b¯gÃÄsolanezumabÁ{þH¹êÅ祢±Ñ¡A¤½¥q¥»¨Ó´Á¬ß¡A¥¦¦¨¬°¦³®Ä´î½w¦Ñ¦~è§b¯g´c¤ÆªººÓÃĪ«¡C
¸Ó¤½¥q«ü¥X¡A¥¦¥i¯à¦b2018¦~§À±À¥X¨â´Ú·sÃÄ¡A¤À§OªvÀø¨ÅÀù©M°¾ÀYµh¡C¬ü°ê¹ª«¤ÎÃĪ«ºÞ²z§½¥¿¦b¼f¬dabemaciclib¡A¥¦¥Î¨ÓªvÀø´c¤Æªº¨ÅÀù¡C